Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents

Current Opinion in Oncology

Volumn 21, Issue 3, 2009, Pages 232-237

  Saba, Nabil F ^a,b   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Chemotherapy; Head and neck cancer; Squamous cell carcinoma; Systemic therapy

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; PACLITAXEL; PALIFERMIN; PLACEBO; PLATINUM; SORAFENIB; SULINDAC; VANDETANIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ADVANCED CANCER; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG SAFETY; DRUG TOLERABILITY; HEAD AND NECK CARCINOMA; HUMAN; LARYNGECTOMY; MAXIMUM TOLERATED DOSE; MESENTERIC VEIN THROMBOSIS; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; DISEASE COURSE; DRUG EFFECT; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE;

EID: 67650391470     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832a56b3     Document Type: Review

References (45)

1. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92:709-720.
2. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100:261-269. Study shows the better clinical outcome for HPV positive head and neck cancer versus HPV negative disease.
3. de Arruda FF, Puri DR, Zhung J. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006; 64:363-373.
4. Pignon JP, Bourhis J, Domenge C, DesignéL. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355:949-955.
5. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92-98.
6. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22:4665-4673.
7. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091-2098.
8. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Clin Otolaryngol 2007; 32:119.
9. Lee NY, de Arruda FF, Puri DR. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006; 66:966-974.
10. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-1944.
11. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945-1952.
12. Forastiere AA, Geopfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091-2098.
13. Forastiere M, Weber RS, Pajak T. Long-term results of intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 2006; 24:284s; abstract 5517.
14. Pignon JP, le Maǐtre A, Bourhis J, MACH-NC Collaborative Group. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007; 69 (2 Suppl):S112-S114.
15. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-1715. Study proved that induction therapy with a taxane-based regimen is superior to a nontaxane regimen in terms of improvement in overall and disease-free survival study established the superiority of the TPF regimen (docetaxel, cisplatin and 5-FU) to a nontaxane-containing regimen (cisplatin and 5-FU) when used in sequential model in treating locally advanced SCCHN.
16. Vermorken JB, Remenar E, Van Herpen CV, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357:1695-1704. Study established the superiority of the TPF regimen (docetaxel, cisplatin and 5-FU) to a nontaxane-containing regimen (cisplatin and 5-FU) when used in sequential model in treating locally advanced SCCHN.
17. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000; 18:1652-1661.
18. Hitt R, López A, Martínez-Trufero J. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23:8636-8645.
19. Hitt R, Lopez-Pousa JGA, García-Giron AB, et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2006; 24; abstract 5515.
20. Paccagnella A, Buffoli A, Koussis H, et al. Randomized phase II trial of induction TPF followed by CT/RT versus CT/RT in locally advanced carcinoma of the head and neck. J Clin Oncol 2008; 26; abstract 6000. This randomized phase II trial favored the induction regimen over the standard concurrent therapy in terms of need for surgical salvage.
21. Rubin Grandis J, Melhem MF, Gooding WE, et al. Tumor levels of TGF-alpha and EGFR protein predict survival in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1998; 90:824-832.
22. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171-2177. One of the very few studies that assessed the response to cetuximab alone in recurrent metastatic SCCHN.
23. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5440-5442.
24. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85.
25. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-1987.
26. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007; 25:2178-2183.
27. Ji H, Zhao X, Yuza Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 2006; 103:7817-7822. doi: 10.1073/pnas.0510284103.
28. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19:3234-3243.
29. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
30. Seiwert TY, Haraf DJ, Cohen EEZ, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2007; 26:1732-1741.
31. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2007; 26:2489-2496.
32. Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007; 25:4880-4886.
33. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5440-5442.
34. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-1127. This study showed a superior clinical outcome (superior overall survival) with the addition of cetuximab to platinum-based therapy in recurrent metastatic disease and is practice shifting for this indication. It is the first study to show significant improvement in overall survival compared with chemotherapy in this patient population.
35. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85.
36. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-1987.
37. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2006; 24:724.
38. Kim ES, Kies MS, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J Clin Oncol 2007; 25 (Part 1):18S; abstract 6013. This phase II study combining chemotherapy with an EGFR TKI showed very good responses to the combination.
39. Saba N, Shin DM, Khuri FR. Targeting angiogenesis in head and neck cancer. Curr Cancer Drug Target 2007; 7:325-334. This is a comprehensive review of the role of angiogenesis in SCCHN with an overview of preclinical and clinical information on the subject.
40. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25:3766-3773. This study showed that sorafenib was well tolerated and had modest anticancer activity comparable in this group of patients. Further development in combination with radiation or other agents may be warranted. The use of sorafenib is not considered a standard of care in this setting.
41. Vokes E, Cohen E, Mauer A, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol 2005; 23:501S; abstract 5504.
42. Kies MS, Gibson MK, Kim SW, et al. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): an interim analysis. J Clin Oncol 2008; 26 (May Suppl); abstract 6072.
43. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358:1160-1174.
44. Agulnik M, Cohen EE, Cohen RB, et al. A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). J Clin Oncol 2006; 24 (Part I:18S; abstract 5566.
45. Le Tourneau C, Siu LL. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 2008; 20:256-263. This is a comprehensive review on the different targeted therapeutic approaches currently under investigation for the treatment of HNCA.